{"id":449937,"date":"2021-03-03T15:29:13","date_gmt":"2021-03-03T20:29:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449937"},"modified":"2021-03-03T15:29:13","modified_gmt":"2021-03-03T20:29:13","slug":"rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/","title":{"rendered":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW"},"content":{"rendered":"
\n

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — WHY: <\/strong>Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.<\/strong><\/p>\n

\n SO WHAT:<\/strong> If you purchased Immunovant securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

\n WHAT TO DO NEXT: <\/strong>To join the Immunovant class action, go to http:\/\/www.rosenlegal.com\/cases-register-2044.html<\/a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com<\/a> or cases@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021<\/strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

\n WHY ROSEN LAW: <\/strong>We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs\u2019 Bar. Many of the firm\u2019s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

\n DETAILS OF THE CASE: <\/strong>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Health Sciences Acquisitions Corporation had performed inadequate due diligence into Immunovant Sciences Ltd. prior to the merger, and\/or ignored or failed to disclose safety issues with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA); (3) the foregoing foreseeably diminished IMVT-1401\u2019s prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Immunovant class action, go to http:\/\/www.rosenlegal.com\/cases-register-2044.html<\/a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com<\/a> or cases@rosenlegal.com<\/a> for information on the class action.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor\u2019s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Laurence Rosen, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Phillip Kim, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0New York, NY 10016
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0lrosen@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0pkim@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0cases@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0www.rosenlegal.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021. SO WHAT: If you purchased Immunovant securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO … <\/p>\n

Continue reading “ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021. SO WHAT: If you purchased Immunovant securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO … Continue reading "ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T20:29:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\\\/k\\\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW\",\"datePublished\":\"2021-03-03T20:29:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/\"},\"wordCount\":675,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/\",\"name\":\"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\\\/k\\\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=\",\"datePublished\":\"2021-03-03T20:29:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\\\/k\\\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/","og_locale":"en_US","og_type":"article","og_title":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","og_description":"NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the \u201cClass Period\u201d). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021. SO WHAT: If you purchased Immunovant securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO … Continue reading \"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T20:29:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW","datePublished":"2021-03-03T20:29:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/"},"wordCount":675,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/","name":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=","datePublished":"2021-03-03T20:29:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk1OSM0MDQ3MjcxIzIwMjA0MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-and-longstanding-firm-encourages-immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f\/k\/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline \u2013 IMVT, HSACU, HSAC, HSACW"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}